Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sizable Layoffs Hit Four Life Science Companies

Mid-year doldrums are hitting as multiple pharmaceutical and biotech companies have initiated layoffs across the United States.

Read More »

Gilead Sciences Cuts 150 Sales Jobs

The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.

Read More »

Novelion to Cut Jobs in Restructuring

Following a disappointing 2017 that included an agreement to pay $40 million to resolve criminal charges against its subsidiary Aegerion, Canada-based Novelion Therapeutics will slash an unknown number of jobs as it initiates “significant cost reduction plans.”

Read More »

Sanofi to Eliminate 400 U.S. Jobs

Paris, France-based Sanofi announced major restructuring involving layoffs. About 400 jobs cut will be in the U.S.

Read More »

Teva’s Job Cuts Hit 208 Philadelphia Employees

Cuts implemented by Israel-based Teva Pharmaceutical hit the shores of the United States. The company is laying off 208 people in the Philadelphia area.

Read More »

Ironshore Laid Off Staff, Quietly Closed Down

Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.

Read More »

OvaScience Pinks Slips Nearly 50 Percent of Workforce

OvaScience is restructuring to cut costs. As part of that process, the company is laying off about half of its staff.

Read More »

265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.

Read More »

Israel’s Protalix to Slash 20 Percent of Workforce

Share prices for Protalix Biotherapeutics were up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease. Despite that positive news on its pipeline, Protalix is reportedly set to terminate 50 employees, which amounts to about 20 percent of its workforce.

Read More »

Teva Announces New Organization Structure

Teva Pharmaceutical Industries announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom